SG10201609250QA - Drug for preventing and/or treating polycystic kidney disease - Google Patents

Drug for preventing and/or treating polycystic kidney disease

Info

Publication number
SG10201609250QA
SG10201609250QA SG10201609250QA SG10201609250QA SG10201609250QA SG 10201609250Q A SG10201609250Q A SG 10201609250QA SG 10201609250Q A SG10201609250Q A SG 10201609250QA SG 10201609250Q A SG10201609250Q A SG 10201609250QA SG 10201609250Q A SG10201609250Q A SG 10201609250QA
Authority
SG
Singapore
Prior art keywords
drug
preventing
kidney disease
polycystic kidney
treating polycystic
Prior art date
Application number
SG10201609250QA
Inventor
Hiroyuki Fujiki
Miki Aihara
Shizuo Kinoshita
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG10201609250QA publication Critical patent/SG10201609250QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10201609250QA 2012-05-31 2013-05-30 Drug for preventing and/or treating polycystic kidney disease SG10201609250QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653524P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
SG10201609250QA true SG10201609250QA (en) 2016-12-29

Family

ID=48670042

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407368VA SG11201407368VA (en) 2012-05-31 2013-05-30 Drug for preventing and/or treating polycystic kidney disease
SG10201609250QA SG10201609250QA (en) 2012-05-31 2013-05-30 Drug for preventing and/or treating polycystic kidney disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407368VA SG11201407368VA (en) 2012-05-31 2013-05-30 Drug for preventing and/or treating polycystic kidney disease

Country Status (31)

Country Link
US (7) US9636382B2 (en)
EP (1) EP2854815B1 (en)
JP (4) JP6116591B2 (en)
KR (2) KR102127180B1 (en)
CN (2) CN104334176B (en)
AR (1) AR091205A1 (en)
AU (3) AU2013268343B2 (en)
BR (1) BR112014029573A2 (en)
CA (1) CA2873365A1 (en)
CO (1) CO7160102A2 (en)
CY (1) CY1120490T1 (en)
DK (1) DK2854815T3 (en)
EA (1) EA036062B1 (en)
ES (1) ES2654768T3 (en)
HK (1) HK1206992A1 (en)
HR (1) HRP20180040T1 (en)
HU (1) HUE035158T2 (en)
IL (2) IL235623A0 (en)
LT (1) LT2854815T (en)
MX (1) MX366121B (en)
MY (1) MY174625A (en)
NO (1) NO2888775T3 (en)
NZ (1) NZ630118A (en)
PH (2) PH12014502558A1 (en)
PL (1) PL2854815T3 (en)
PT (1) PT2854815T (en)
SG (2) SG11201407368VA (en)
SI (1) SI2854815T1 (en)
TW (2) TWI633887B (en)
WO (1) WO2013180310A1 (en)
ZA (1) ZA201408411B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343982B1 (en) 2008-09-17 2017-03-22 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
TWI633887B (en) 2012-05-31 2018-09-01 大塚製藥股份有限公司 Drug for preventing and/or treating polycystic kidney disease
WO2014104412A1 (en) 2012-12-28 2014-07-03 Otsuka Pharmaceutical Co., Ltd. Injectable depot formulation comprising optically active tolvaptan and process of producing the same
TW201605488A (en) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 Drug for preventing and/or treating polycystic kidney disease
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
EP3405211A4 (en) * 2016-01-21 2019-10-09 Chiasma Inc. Oral octreotide for the treatment of disease
WO2019118272A1 (en) * 2017-12-11 2019-06-20 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP4015860A4 (en) 2019-08-14 2022-09-28 Autodyn Sys Inc. Clutch system interlocking with accelerator and brake pedal
US11781606B2 (en) 2019-10-16 2023-10-10 Autodyn Sys Inc. Rotary shaft assembly
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20230158041A1 (en) * 2021-11-22 2023-05-25 Otsuka Pharmaceutical Co.,Ltd. Methods and compositions for treating autosomal dominant polycystic kidney disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450097B1 (en) 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
JP4154765B2 (en) 1998-09-28 2008-09-24 ダイキン工業株式会社 Ceiling-mounted air blower
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AR044852A1 (en) * 2003-06-24 2005-10-05 Novartis Ag A PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION THAT INCLUDES A SOMATOSTATINE ANALOG
ES2533007T3 (en) 2005-12-27 2015-04-06 Otsuka Pharmaceutical Co., Ltd. Water soluble benzoacepin compound and its pharmaceutical composition
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
EP2007370B1 (en) 2006-03-31 2013-12-18 Erasmus University Medical Center Rotterdam Novel composition for tumor growth control
AU2007255416A1 (en) 2006-06-08 2007-12-13 Novartis Ag Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist
TWI459947B (en) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd Benzazepine compound and pharmaceutical preparation
TWI633887B (en) 2012-05-31 2018-09-01 大塚製藥股份有限公司 Drug for preventing and/or treating polycystic kidney disease

Also Published As

Publication number Publication date
CN107625953A (en) 2018-01-26
IL235623A0 (en) 2015-01-29
SG11201407368VA (en) 2015-01-29
TW201827056A (en) 2018-08-01
US20160058841A1 (en) 2016-03-03
PT2854815T (en) 2017-12-20
NO2888775T3 (en) 2018-08-04
CO7160102A2 (en) 2015-01-15
US20190117666A1 (en) 2019-04-25
PL2854815T3 (en) 2018-03-30
US20190374549A1 (en) 2019-12-12
US11013746B2 (en) 2021-05-25
IL253441A0 (en) 2017-09-28
KR102211354B1 (en) 2021-02-03
KR20200034811A (en) 2020-03-31
MX366121B (en) 2019-06-27
BR112014029573A2 (en) 2017-06-27
US9669075B2 (en) 2017-06-06
NZ630118A (en) 2016-07-29
PH12014502558B1 (en) 2015-01-21
US9636382B2 (en) 2017-05-02
JP6116591B2 (en) 2017-04-19
EA036062B1 (en) 2020-09-22
CN104334176A (en) 2015-02-04
SI2854815T1 (en) 2018-02-28
WO2013180310A1 (en) 2013-12-05
KR102127180B1 (en) 2020-06-29
PH12014502558A1 (en) 2015-01-21
CA2873365A1 (en) 2013-12-05
HRP20180040T1 (en) 2018-02-09
AU2019202158B2 (en) 2020-06-25
TWI704919B (en) 2020-09-21
CN104334176B (en) 2018-01-02
EA201492279A1 (en) 2015-05-29
EP2854815B1 (en) 2017-11-22
JP6724085B2 (en) 2020-07-15
ES2654768T3 (en) 2018-02-15
US20170239265A1 (en) 2017-08-24
HK1206992A1 (en) 2016-01-22
AR091205A1 (en) 2015-01-21
US11957691B2 (en) 2024-04-16
JP2017110029A (en) 2017-06-22
TWI633887B (en) 2018-09-01
HUE035158T2 (en) 2018-05-02
AU2013268343A1 (en) 2014-11-27
JP2015517974A (en) 2015-06-25
US20220241293A1 (en) 2022-08-04
DK2854815T3 (en) 2018-01-22
JP6938705B2 (en) 2021-09-22
CY1120490T1 (en) 2019-07-10
MY174625A (en) 2020-05-03
TW201400118A (en) 2014-01-01
ZA201408411B (en) 2016-09-28
US20150141338A1 (en) 2015-05-21
US11147821B2 (en) 2021-10-19
US20170196877A1 (en) 2017-07-13
LT2854815T (en) 2018-02-12
AU2013268343B2 (en) 2017-06-01
AU2019202158A1 (en) 2019-04-18
EP2854815A1 (en) 2015-04-08
JP2019001801A (en) 2019-01-10
KR20150016597A (en) 2015-02-12
MX2014014476A (en) 2015-02-12
JP2020117535A (en) 2020-08-06
AU2017202757A1 (en) 2017-05-18
PH12018501227A1 (en) 2020-09-14

Similar Documents

Publication Publication Date Title
IL274988A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL253441A0 (en) Drug for preventing and/or treating polycystic kidney disease
EP2906208A4 (en) Therapeutic treatment
EP2862620A4 (en) Discharge-gas treatment system
ZA201408855B (en) Flocculation treatment agent
GB2521289B (en) Formation treatment system
EP2777576A4 (en) Treatment system
EP2789306A4 (en) Treatment system
EP2803328A4 (en) Treatment system
HK1205464A1 (en) Preventing or treating periodontal disease
EP2870971A4 (en) Drug for preventing/treating ocular disease
GB2507464B (en) Controlled drug destruction
EP2869796A4 (en) Patient treatment system
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201207007D0 (en) Electromagnetic treatment